VXRTVaxart, Inc.

Nasdaq vaxart.com


$ 0.94 $ 0.08 (9.24 %)    

Wednesday, 15-May-2024 15:59:50 EDT
QQQ $ 452.83 $ 6.97 (1.56 %)
DIA $ 399.31 $ 3.70 (0.94 %)
SPY $ 529.09 $ 6.48 (1.24 %)
TLT $ 92.14 $ 1.24 (1.36 %)
GLD $ 220.89 $ 2.80 (1.28 %)
$ 0.9446
$ 0.88
$ 0.94 x 600
$ 0.00 x 0
$ 0.87 - $ 0.95
$ 0.53 - $ 1.59
2,110,742
na
164.23M
$ -0.88
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-13-2024 03-31-2024 10-Q
2 03-14-2024 12-31-2023 10-K
3 11-02-2023 09-30-2023 10-Q
4 08-03-2023 06-30-2023 10-Q
5 05-04-2023 03-31-2023 10-Q
6 03-15-2023 12-31-2022 10-K
7 11-09-2022 09-30-2022 10-Q
8 08-08-2022 06-30-2022 10-Q
9 05-09-2022 03-31-2022 10-Q
10 02-24-2022 12-31-2021 10-K
11 11-04-2021 09-30-2021 10-Q
12 08-05-2021 06-30-2021 10-Q
13 05-06-2021 03-31-2021 10-Q
14 02-25-2021 12-31-2020 10-K
15 11-12-2020 09-30-2020 10-Q
16 08-06-2020 06-30-2020 10-Q
17 05-12-2020 03-31-2020 10-Q
18 03-19-2020 12-31-2019 10-K
19 11-12-2019 09-30-2019 10-Q
20 08-08-2019 06-30-2019 10-Q
21 05-09-2019 03-31-2019 10-Q
22 02-06-2019 12-31-2018 10-K
23 11-13-2018 09-30-2018 10-Q
24 08-10-2018 06-30-2018 10-Q
25 05-15-2018 03-31-2018 10-Q
26 02-06-2018 12-31-2017 10-Q
27 11-07-2017 09-30-2017 10-Q
28 09-01-2017 06-30-2017 10-K
29 05-08-2017 05-02-2017 10-Q
30 02-06-2017 12-31-2016 10-Q
31 11-08-2016 09-30-2016 10-Q
32 09-13-2016 06-30-2016 10-K
33 05-10-2016 03-31-2016 10-Q
34 02-08-2016 12-31-2015 10-Q
35 11-06-2015 09-30-2015 10-Q
36 09-11-2015 06-30-2015 10-K
37 05-08-2015 03-31-2015 10-Q
38 02-06-2015 12-31-2014 10-Q
39 11-07-2014 09-30-2014 10-Q
40 09-30-2014 06-30-2014 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 vaxart-stock-climbs-after-blockbuster-q1-revenue

Vaxart reported quarterly losses of 14 cents per share, inline with the analyst consensus estimate. Quarterly sales clocked in ...

 vaxart-to-meet-with-fda-in-mid-2024-to-evaluate-clinical-data-and-discuss-next-steps-for-its-norovirus-program-anticipates-cash-runway-into-late-q4-of-2024

These data will inform potential next steps, such as potentially conducting a Phase 2b study and potentially a GII.4 challenge ...

 vaxart-q1-2024-gaap-eps-014-inline-sales-2181m-beat-800000k-estimate

Vaxart (NASDAQ:VXRT) reported quarterly losses of $(0.14) per share which met the analyst consensus estimate. The company repo...

 vaxart-announces-results-for-its-bivalent-norovirus-vaccine-candidate-in-lactating-mothers-long-term-goal-is-to-provide-protection-to-infants-through-passive-antibody-transfer

Antibody rise observed in lactating mothers and in their breast milk Long-term goal is to provide protection to infants through...

 recap-vaxart-q4-earnings
Recap: Vaxart Q4 Earnings
03/14/2024 20:20:17

 vaxart-q4-2023-gaap-eps-012-beats-014-estimate-sales-3245m-beat-1250m-estimate

Vaxart (NASDAQ:VXRT) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.14) by 14....

 earnings-scheduled-for-march-14-2024

Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter.

 vaxarts-earnings-a-preview
Vaxart's Earnings: A Preview
03/13/2024 19:01:18

 vaxart-appoints-steven-lo-as-president-and-ceo

Michael J. Finney, Ph.D. to Continue as Chairman of the Board of Directors

 vaxart-announces-publication-in-vaccines-of-non-human-primate-preclinical-data-demonstrating-its-next-generation-vaccine-candidates-elicit-mucosal-and-systemic-immunogenicity-and-reduce-viral-shedding-after-sars-cov-2-challenge

—  Data served as foundation for current vaccine candidate for planned Phase 2 research—  Vaxart vaccine candidates elicited st...

 why-amd-shares-are-trading-lower-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Shares of Advanced Micro Devices, Inc. (NASDAQ: AMD) shares declined 3.8% to $165.49 following fourth-quarter results. AMD rep...

 b-riley-securities-upgrades-vaxart-to-buy-announces-2-price-target

B. Riley Securities analyst Mayank Mamtani upgrades Vaxart (NASDAQ:VXRT) from Neutral to Buy and announces $2 price target.

 vaxart-receives-927m-barda-project-nextgen-award-to-prepare-for-phase-2b-clinical-study-evaluating-its-covid-19-oral-pill-vaccine-candidate

- 10,000-subject Phase 2b study would evaluate Vaxart's next generation oral pill XBB COVID-19 vaccine against an approved ...

 whats-going-on-with-vaxart-stock-today

Vaxart shares are trading higher by around 8% Wednesday afternoon. The company recently secured a contract from the U.S. Govern...

 whats-going-on-with-vaxart-vxrt-stock

Vaxart shares are trading higher by 17.8% Tuesday morning amid multiple news items. The company recently secured a contract fro...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION